NCT05726526 CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
| NCT ID | NCT05726526 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manitoba |
| Condition | Chronic Kidney Disease Stage 5 |
| Study Type | INTERVENTIONAL |
| Enrollment | 340 participants |
| Start Date | 2022-06-30 |
| Primary Completion | 2027-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 340 participants in total. It began in 2022-06-30 with a primary completion date of 2027-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.
Eligibility Criteria
Inclusion Criteria: * \>18 years of age * Patient or primary caregiver can read and speak English * Patient or patients substitute decision maker is able to provide informed consent * Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.) * Have stage 5 CKD (2 measurements of eGFR \<15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation, or have \>40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation * Followed in a multidisciplinary CKD clinic Exclusion Criteria: * Inability of self or caregiver assisted self-monitoring using VIEWER
Contact & Investigator
Claudio Rigatto, MD
PRINCIPAL INVESTIGATOR
University of Manitoba
Frequently Asked Questions
Who can join the NCT05726526 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease Stage 5. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05726526 currently recruiting?
Yes, NCT05726526 is actively recruiting participants. Contact the research team at crigatto@sogh.mb.ca for enrollment information.
Where is the NCT05726526 trial being conducted?
This trial is being conducted at Winnipeg, Canada, Winnipeg, Canada, Winnipeg, Canada, London, Canada and 1 additional location.
Who is sponsoring the NCT05726526 clinical trial?
NCT05726526 is sponsored by University of Manitoba. The principal investigator is Claudio Rigatto, MD at University of Manitoba. The trial plans to enroll 340 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.